Want to join the conversation?
$BAX 2Q15 PR: Segment Sales: Sales within Medical Products totaled $2.5Bil, a decline of 9%. Excluding impact of FX, Medical Products sales were comparable to prior year. On a reported basis, BioScience sales of $1.4Bil declined 2% compared to 2Q14. Excluding impact of FX, BioScience sales increased 7% driven by solid growth across the portfolio.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!